Targeted therapy of post-transplant lymphoproliferative disease / 中华实用儿科临床杂志

ABSTRACT

Post-transplant lymphoproliferative disease(PTLD) results from the uncontrolled proliferation of lymphocytes after hematopoietic stem cell transplantation and solid organ transplantation.PTLD greatly reduces the survival of both patients and grafts.The treatments for PTLD include reducing the use of immunosuppressive agents, chemotherapy, EB virus-specific cytotoxic T lymphocytes (CTL), B lymphocyte depletion therapy, targeted inhibitors, etc.However, all of them have shortages.Specific biological target drugs aiming at a certain link in the pathogenesis of PTLD show a good curative effect and small adverse reactions, and thus serve as new options for its prevention and treatment.Because of the limited data, clinical studies are still needed to confirm these drugs.In this article, the application of targeted therapy in the treatment of PTLD was summarized.